Psychiatry related information on IMPA1

• Inositol monophosphatase is widely held to be the therapeutic target for inhibition by lithium ion in the treatment of bipolar disorder [1].

High impact information on IMPA1

• Inositol monophosphatase is a key enzyme of the inositol phosphate second messenger signaling pathway [2].
• Using a partially purified myo-inositol monophosphatase preparation derived from bovine brain, we examined the effects of lithium, carbamazepine, and valproate on the IMPase reaction [3].
• Inhibition of myo-inositol monophosphatase (IMPase), which converts myo-inositol monophosphates to myo-inositol, results in increased levels of myo-inositol monophosphates and decreased myo-inositol available for the resynthesis of inositol phospholipids [3].
• These results demonstrate that (1) lithium inhibited IMPase activity in the low millimolar range, (2) carbamazepine stimulated the IMPase reaction beginning in the low-micromolar range, and (3) valproate did not demonstrate any stimulation or inhibition of IMPase [3].
• Bovine inositol monophosphatase. Modification, identification and mutagenesis of reactive cysteine residues [4].

Biological context of IMPA1

• The 6-OH group of D-inositol 1-phosphate serves as an H-bond donor in the catalytic hydrolysis of the phosphate ester by inositol monophosphatase [5].

Associations of IMPA1 with chemical compounds

• 1. Bovine inositol monophosphatase reacts with thiol reagents such as 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB), N-ethylmaleimide (NEM) and iodoacetic acid (IAA) [4].
• Bovine inositol monophosphatase. The identification of a histidine residue reactive to diethylpyrocarbonate [6].
• Bovine inositol monophosphatase. Ligand binding to pyrene-maleimide-labelled enzyme [7].
• This paper describes a continuous assay for the enzyme inositol monophosphatase which has been developed using a new substrate, the fluorescent compound 4-methylumbelliferyl phosphate [8].

References